STAND.
COM. REP. NO. 848
Honolulu, Hawaii
, 2021
RE: H.B. No. 542
H.D. 1
Honorable Scott K. Saiki
Speaker, House of Representatives
Thirty-First State Legislature
Regular Session of 2021
State of Hawaii
Sir:
Your Committee on Consumer Protection & Commerce, to which was referred H.B. No. 542 entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT,"
begs leave to report as follows:
The purpose of this measure is to remove the prescription drug Epidiolex and approved generic versions of that drug that contain cannabidiol derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols from schedule V of the Uniform Controlled Substances Act.
Your Committee finds that the Agriculture Improvement Act of 2018 (P.L. 115-334), modified the regulatory controls over cannabis, tetrahydrocannabinols, and other cannabis-related constituents in the federal Controlled Substances Act. In April 2020, the United States Drug Enforcement Agency notified the manufacturer of Epidiolex of its removal from the federal schedule V and officially removed its designation through an interim final rule issued in August 2020. This measure is necessary to conform the Uniform Controlled Substances Act with the federal treatment of Epidiolex and approved generic versions of that drug.
Your Committee has amended this measure by:
(1) Changing the effective date to January 1, 2050, to encourage further discussion; and
(2) Making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.
As affirmed by the record of votes of the members of your Committee on Consumer Protection & Commerce that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 542, as amended herein, and recommends that it pass Third Reading in the form attached hereto as H.B. No. 542, H.D. 1.
Respectfully submitted on behalf of the members of the Committee on Consumer Protection & Commerce,
|
|
|
____________________________ AARON LING JOHANSON, Chair |
|
|
|
|